Ring Therapeutics

We're attending #ESGCT2024! Our poster presentation will highlight successful genomic payload expansion of our novel AnelloVector viral vectors and further validates it as the first gene delivery vector system based on the human commensal anellovirus. Read our press release to learn more about how we're advancing the next generation of #GeneticMedicines through this unique approach: https://bit.ly/4dUP6EQ

Thrilled to share that our Chief Technology Officer, Konstantin Konstantinov, has been selected to deliver the opening keynote lecture for the upcoming #SPICA Conference taking place in in Milan, Italy, from October 15-19th. The remarks will highlight some of the latest breakthroughs across the Preparative and Industrial Chromatography field, such as our novel AnelloBricks™ platform that offers a highly modular, versatile, and scalable manufacturing solution for #GeneticMedicines. Learn more here: https://lnkd.in/ePQh7KXm

At Ring, our values drive our team of pioneers forward. Together as #OneRing, we are dedicated to fostering an audacious, inclusive, and resilient culture as we work to build a better future for patients.

Did you know our Anellovectors can be engineered to have an expanded payload capacity beyond natural anellovirus genome sizes? Data presented at #ASGCT2024 unveiled the broadened therapeutic potential of this novel class of viral vectors across a wide range of disease areas. Learn how we’re advancing the next generation of programmable medicines here: https://bit.ly/47wjJio

We're thrilled to share our recent publication in Nature Portfolio showcasing the unique structure of anelloviruses. By leveraging their structurally-derived immune evasion properties, our team is developing potentially safer vectors through our novel Anellogy™ platform to transform the future of #GeneticMedicines. To learn more about anelloviruses and the promise they hold in the #GeneticMedicine space, read here: https://lnkd.in/gCdPNqeD

Check out the latest episode of CGTLive where our Chief Medical Officer and Head of Translational Research, Chris Wright, MD, PhD, highlighted our latest data findings unveiled at ASGCT 2024. To learn more about the promise of anelloviruses and how we’re harnessing their natural capabilities through our novel Anellogy TM Platform, watch the full interview here: https://bit.ly/3A48ZLs

🧬🔬 Happy #NationalInternDay! Our co-ops Kesav Ram Singh, Maddie Schanen, Dhatri Mishra, Tyler Gauthier, Tanisha Garg, Sudhan Dhavle, Robert Fletcher, Willow Klein, Utsav Mesvani, Tanmay Nimbulkar, and Sally Howard are helping us push the boundaries of what is possible and we’re so thankful for their hard work and dedication to the team. The future of #biotech is bright, and we can’t wait to see where these #FutureLeaders end up.

🏓 Last month, our team swapped lab coats for paddles and had a blast on the #Pickleball court for our summer outing. It was an evening full of games, laughs, and celebrations in honor of our 7th anniversary! Check out these photos from the event!

Earlier this month, we closed our offices for a #SummerShutdown to allow our team to rest, rejuvenate, and participate in summer activities that matter to them! At Ring, we prioritize a healthy work-life-balance to ensure our team remains resilient, motivated, and well-rested so we can continue to revolutionize programmable medicines.

Exciting news from Flagship Pioneering as they announce the raise of $3.6 billion to fuel breakthrough innovations that transform human health and sustainability. We are proud to be #FlagshipFounded and part of an ecosystem of companies – present and future – taking bold scientific leaps to deliver a better future for all.